Actively Recruiting
Randomized, Double-Blind Study Comparing Oral Orelabrutinib to Placebo for Treatment of Primary Progressive Multiple Sclerosis
Led by Zenas BioPharma (USA), LLC · Updated on 2026-11-03
705
Participants Needed
83
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.
CONDITIONS
Brief Title
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Research Team
P
Patient and Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here